Stay updated with breaking news from Steven Romano. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Study met primary endpoint and demonstrated highly significant reductions in Lp to week 36 Lipoprotein reduction was consistent with phase 1 results Topline 48-week data expected in 2Q 2024 ...
Dr. Romano will succeed Dr. Giles Campion, CMO and Head of R&D, following his retirement by year-end Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative
/PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that Dr....
/PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced the recipient of 2022's Advancing...
-- Winning project hopes to unlock invaluable insights on how ECP could improve quality of life and clinical outcomes in chronic lung allograft dysfunction -- DUBLIN, Nov. 16, 2022 /PRNewswire/